214 related articles for article (PubMed ID: 26467507)
1. Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.
Twitty CG; Diago OR; Hogan DJ; Burrascano C; Ibanez CE; Jolly DJ; Ostertag D
Hum Gene Ther Methods; 2016 Feb; 27(1):17-31. PubMed ID: 26467507
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Takahashi M; Valdes G; Hiraoka K; Inagaki A; Kamijima S; Micewicz E; Gruber HE; Robbins JM; Jolly DJ; McBride WH; Iwamoto KS; Kasahara N
Cancer Gene Ther; 2014 Oct; 21(10):405-410. PubMed ID: 25301172
[TBL] [Abstract][Full Text] [Related]
3. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Huang TT; Parab S; Burnett R; Diago O; Ostertag D; Hofman FM; Espinoza FL; Martin B; Ibañez CE; Kasahara N; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Hum Gene Ther; 2015 Feb; 26(2):82-93. PubMed ID: 25419577
[TBL] [Abstract][Full Text] [Related]
4. Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Hogan DJ; Zhu JJ; Diago OR; Gammon D; Haghighi A; Lu G; Das A; Gruber HE; Jolly DJ; Ostertag D
Clin Cancer Res; 2018 Oct; 24(19):4680-4693. PubMed ID: 29945998
[No Abstract] [Full Text] [Related]
5. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
Perez OD; Logg CR; Hiraoka K; Diago O; Burnett R; Inagaki A; Jolson D; Amundson K; Buckley T; Lohse D; Lin A; Burrascano C; Ibanez C; Kasahara N; Gruber HE; Jolly DJ
Mol Ther; 2012 Sep; 20(9):1689-98. PubMed ID: 22547150
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Cloughesy TF; Landolfi J; Hogan DJ; Bloomfield S; Carter B; Chen CC; Elder JB; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu PL; Piccioni D; Walbert T; Chu A; Das A; Diago OR; Gammon D; Gruber HE; Hanna M; Jolly DJ; Kasahara N; McCarthy D; Mitchell L; Ostertag D; Robbins JM; Rodriguez-Aguirre M; Vogelbaum MA
Sci Transl Med; 2016 Jun; 8(341):341ra75. PubMed ID: 27252174
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
Inoko K; Hiraoka K; Inagaki A; Takahashi M; Kushibiki T; Hontani K; Takano H; Sato S; Takeuchi S; Nakamura T; Tsuchikawa T; Shichinohe T; Gruber HE; Jolly DJ; Kasahara N; Hirano S
Cancer Gene Ther; 2018 Aug; 25(7-8):184-195. PubMed ID: 29735994
[TBL] [Abstract][Full Text] [Related]
8. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
[TBL] [Abstract][Full Text] [Related]
9. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
Hiraoka K; Inagaki A; Kato Y; Huang TT; Mitchell LA; Kamijima S; Takahashi M; Matsumoto H; Hacke K; Kruse CA; Ostertag D; Robbins JM; Gruber HE; Jolly DJ; Kasahara N
Neuro Oncol; 2017 Jul; 19(7):918-929. PubMed ID: 28387831
[TBL] [Abstract][Full Text] [Related]
10. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Cloughesy TF; Landolfi J; Vogelbaum MA; Ostertag D; Elder JB; Bloomfield S; Carter B; Chen CC; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu P; Piccioni D; Accomando W; Diago OR; Hogan DJ; Gammon D; Kasahara N; Kheoh T; Jolly DJ; Gruber HE; Das A; Walbert T
Neuro Oncol; 2018 Sep; 20(10):1383-1392. PubMed ID: 29762717
[TBL] [Abstract][Full Text] [Related]
11. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Hirschowitz EA; Ohwada A; Pascal WR; Russi TJ; Crystal RG
Hum Gene Ther; 1995 Aug; 6(8):1055-63. PubMed ID: 7578418
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
13. Highly efficient gene transfer to solid tumors in vivo by tumor-selective replicating retrovirus vectors.
Lu YC; Luo YP; Wang YW; Tai CK
Int J Mol Med; 2010 May; 25(5):769-75. PubMed ID: 20372821
[TBL] [Abstract][Full Text] [Related]
14. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Yagiz K; Huang TT; Lopez Espinoza F; Mendoza D; Ibañez CE; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2016 Oct; 18(10):1390-401. PubMed ID: 27166379
[TBL] [Abstract][Full Text] [Related]
15. Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells.
Pederson LC; Vickers SM; Buchsbaum DJ; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
J Gastrointest Surg; 1998; 2(3):283-91. PubMed ID: 9841986
[TBL] [Abstract][Full Text] [Related]
16. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
17. Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Wang D; Ruan H; Hu L; Lamborn KR; Kong EL; Rehemtulla A; Deen DF
Cancer Gene Ther; 2005 Mar; 12(3):276-83. PubMed ID: 15650767
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Miller CR; Williams CR; Buchsbaum DJ; Gillespie GY
Cancer Res; 2002 Feb; 62(3):773-80. PubMed ID: 11830532
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Hiraoka K; Kimura T; Logg CR; Tai CK; Haga K; Lawson GW; Kasahara N
Cancer Res; 2007 Jun; 67(11):5345-53. PubMed ID: 17545615
[TBL] [Abstract][Full Text] [Related]
20. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Mitchell LA; Lopez Espinoza F; Mendoza D; Kato Y; Inagaki A; Hiraoka K; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2017 Jul; 19(7):930-939. PubMed ID: 28387849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
